Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Generics Press For Compulsory Licenses Concerns Brand Makers

This article was originally published in PharmAsia News

Executive Summary

Multinational drug makers are voicing concerns about moves in India to impose compulsory licenses that would free others, mainly Indian manufacturers, to make generic copies of their drugs. Indian generics makers are looking into the possibility of using World Trade Organization provisions that allow patents to be overridden during medical emergencies or when cheaper drugs can be exported to least-developed nations. The Trade-Related Aspects of Intellectual Property Rights provision allows patent holders to receive "adequate remuneration." Natco Pharma already has requested compulsory licenses on two cancer drugs, a move that could become part of a trend. A Pfizer official says such a move "would be a clear disregard of Indian patent laws." (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts